SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1852.43 Billion KRW | -13.52% |
| 2022 | 2141.93 Billion KRW | 1.51% |
| 2021 | 2110.12 Billion KRW | 275.31% |
| 2020 | 562.23 Billion KRW | 39.17% |
| 2019 | 403.98 Billion KRW | 0.31% |
| 2018 | 402.71 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1966.4 Billion KRW | 2.52% |
| 2024 Q1 | 1918.05 Billion KRW | 3.54% |
| 2023 Q1 | 2022.25 Billion KRW | -5.59% |
| 2023 FY | 1852.43 Billion KRW | -13.52% |
| 2023 Q4 | 1852.43 Billion KRW | -3.53% |
| 2023 Q3 | 1920.13 Billion KRW | -2.46% |
| 2023 Q2 | 1968.51 Billion KRW | -2.66% |
| 2022 Q3 | 2099.31 Billion KRW | 0.25% |
| 2022 Q2 | 2094.06 Billion KRW | 4.63% |
| 2022 Q1 | 2001.42 Billion KRW | -5.15% |
| 2022 FY | 2141.93 Billion KRW | 1.51% |
| 2022 Q4 | 2141.93 Billion KRW | 2.03% |
| 2021 Q4 | 2110.12 Billion KRW | 9.95% |
| 2021 Q2 | 1791.92 Billion KRW | 4.8% |
| 2021 Q3 | 1919.18 Billion KRW | 7.1% |
| 2021 FY | 2110.12 Billion KRW | 275.31% |
| 2021 Q1 | 1709.92 Billion KRW | 204.13% |
| 2020 Q2 | 403.13 Billion KRW | 2.72% |
| 2020 FY | 562.23 Billion KRW | 39.17% |
| 2020 Q4 | 562.23 Billion KRW | 6.92% |
| 2020 Q3 | 525.85 Billion KRW | 30.44% |
| 2020 Q1 | 392.46 Billion KRW | -2.85% |
| 2019 Q2 | 401.62 Billion KRW | 1.96% |
| 2019 FY | 403.98 Billion KRW | 0.31% |
| 2019 Q3 | 397.06 Billion KRW | -1.14% |
| 2019 Q4 | 403.98 Billion KRW | 1.74% |
| 2019 Q1 | 393.9 Billion KRW | -2.19% |
| 2018 Q4 | 402.71 Billion KRW | 2.44% |
| 2018 Q3 | 393.12 Billion KRW | 0.0% |
| 2018 FY | 402.71 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ORIENT BIO Inc. | 96.98 Billion KRW | -1809.972% |
| Green Cross Holdings Corporation | 3737.7 Billion KRW | 50.439% |
| Green Cross Holdings Corporation | 2643.31 Billion KRW | 29.92% |
| Pharmicell Co., Ltd. | 99.19 Billion KRW | -1767.542% |
| Green Cross Corporation | 2643.31 Billion KRW | 29.92% |
| GeneOne Life Science, Inc. | 151 Billion KRW | -1126.718% |
| Celltrion, Inc. | 19917.53 Billion KRW | 90.699% |
| Samsung Biologics Co.,Ltd. | 16046.19 Billion KRW | 88.456% |
| SK Biopharmaceuticals Co., Ltd. | 723.17 Billion KRW | -156.155% |
| Prestige BioPharma Limited | 711.72 Billion KRW | -160.276% |